ARG1 (Arginase 1) is a human gene located on chromosome 6q23.2 that encodes the cytosolic isoform of arginase, a metalloenzyme that catalyzes the final step of the urea cycle — the hydrolysis of L-arginine to L-ornithine and urea. While its primary metabolic role is in the liver and kidney, ARG1 is also expressed in the brain, where it plays important roles in modulating nitric oxide (NO) production, polyamine synthesis, and immune cell function.
In the central nervous system, arginase activity competes with nitric oxide synthase (NOS) for the shared substrate L-arginine, making it a critical regulator of neuroinflammation and excitotoxicity. Dysregulation of ARG1 has been implicated in Alzheimer's disease, Parkinson's disease, and ALS.
| Attribute |
Value |
| Symbol |
ARG1 |
| Full Name |
Arginase 1 |
| Chromosome |
6q23.2 |
| NCBI Gene ID |
383 |
| OMIM ID |
608313 |
| UniProt ID |
P05089 |
| Ensembl ID |
ENSG00000118526 |
| Protein Class |
Hydrolase, manganese-dependent |
Arginase 1 is a 322-amino acid protein that forms a homotrimeric quaternary structure. Each monomer contains a binuclear manganese cluster at the active site that is essential for catalytic activity.
Key Features:
- Molecular Weight: ~34.9 kDa
- Cellular Location: Cytosol
- Tissue Expression: Liver, kidney, brain (astrocytes, microglia, neurons)
- Induction: IL-4, IL-13, glucocorticoids
- Metal Cofactor: Manganese (Mn²⁺)
- Quaternary Structure: Homotrimer (three identical subunits)
The arginase catalytic mechanism involves:
- Metal Ion Activation: Mn²⁺ ions activate a water molecule
- Nucleophilic Attack: Activated water hydrolyzes arginine
- Ornithine Release: Produces L-ornithine and urea
- Substrate Binding: Arginine binds through guanidinium group
¶ Structural Domains
- N-terminal domain: Contains the active site with manganese cluster
- C-terminal domain: Contributes to trimer formation
- Active site pocket: Deep cleft for arginine binding
- Allosteric regions: Potential drug binding sites
- Km for L-arginine: ~1-10 mM (varies by species)
- Vmax: High catalytic efficiency
- Inhibitors: Boronic acid derivatives, amino acids, metal chelators
- pH Optimum: 9.0-10.0 (optimal for urea production)
ARG1 plays a crucial role in modulating nitric oxide signaling:
- Substrate Competition: Arginase and NOS compete for L-arginine as substrate
- NO Production: By limiting arginine availability, ARG1 reduces NO production
- NOS Coupling: Altered arginase/NOS balance affects NOS coupling and superoxide production
- Peroxynitrite Formation: Uncoupled NOS produces harmful peroxynitrite
The product of arginase activity, L-ornithine, is a precursor for polyamine synthesis:
- Putrescine: Generated by ornithine decarboxylase
- Spermidine: Further converted by spermidine synthase
- Spermine: Final product by spermine synthase
- Polyamines are involved in: cell proliferation, protein synthesis, oxidative stress protection
The polyamine pathway in the brain:
- Arginine → Ornithine: Arginase catalysis
- Ornithine → Putrescine: Ornithine decarboxylase (ODC)
- Putrescine → Spermidine: Spermidine synthase
- Spermidine → Spermine: Spermine synthase
In microglia and astrocytes:
- M2 Polarization: ARG1 is a marker of alternative (M2) activation
- Anti-inflammatory: M2 microglia are generally neuroprotective
- Wound Healing: Promotes tissue repair and remodeling
- Trophic Support: Secretes growth factors
Microglial activation exists on a spectrum:
- M1 (Classical Activation): Pro-inflammatory, cytotoxic
- iNOS, TNF-α, IL-1β, IL-6
- Neurotoxic in chronic states
- M2 (Alternative Activation): Anti-inflammatory, reparative
- ARG1, CD206, YM1, Fizz1
- Neuroprotective functions
ARG1 involvement in AD is complex:
- Neuroinflammation: Altered arginase activity affects cytokine production and glial response to amyloid-beta
- NO Signaling: Modulates NOS activity and oxidative stress
- Memory: Arginase inhibition may improve memory in AD models
- Therapeutic Target: Arginase modulators being explored
Mechanisms in AD:
- Amyloid-beta Interaction: Aβ alters arginase expression
- Tau Pathology: Hyperphosphorylated tau affects arginase
- Oxidative Stress: Arginase affects ROS production
- Synaptic Dysfunction: Alters polyamine signaling
In PD, ARG1 shows altered expression:
- Microglial Activation: Changes in ARG1 correlate with microglial activation state
- Neuroprotection: Arginase activity may protect dopaminergic neurons
- L-DOPA Response: Arginase may influence response to dopaminergic therapy
- α-Synuclein: Interaction with arginase affects aggregation
Key mechanisms:
- Dopaminergic Protection: Ornithine → polyamines support neuron survival
- Microglial Modulation: M2 microglia reduce neuroinflammation
- Mitochondrial Function: Polyamines support mitochondrial health
- Autophagy: Polyamines induce autophagy
ARG1 dysregulation in ALS:
- Motor Neuron Environment: Altered in SOD1 mouse models
- Glial Response: Microglial arginase expression changes during disease progression
- Therapeutic Potential: Modulating arginase may influence disease course
- Excitotoxicity: Arginase affects glutamate metabolism
ARG1 catalyzes the final step of the urea cycle:
L-Arginine → L-Ornithine + Urea
↓
Putrescine → Spermidine → Spermine
- Gluconeogenesis: Ornithine can be converted to glucose
- Glutamate Synthesis: Ornithine → glutamate
- Proline Synthesis: Ornithine → proline
- Creatine Synthesis: Arginine → creatine
Several drug development approaches are underway:
- Small Molecule Inhibitors: Boronic acid derivatives
- Allosteric Modulators: Target non-active sites
- Substrate Analogs: Competitive inhibitors
- Combination Therapy: With NOS inhibitors
Current status:
- Cardiovascular: Arginase inhibitors in trials
- Neurological: Preclinical AD/PD models
- Combination: With existing therapies
ARG1 and related metabolites may serve as:
- Markers of microglial activation
- Indicators of neuroinflammatory state
- Potential biomarkers for disease progression
- Therapeutic response markers
ARG1 knockout in mice reveals:
- Hyperammonemia: Impaired urea cycle function
- Growth Retardation: Developmental abnormalities
- Neurological Deficits: Behavioral changes
- Immune Dysregulation: Altered inflammatory responses
Transgenic overexpression shows:
- Improved Wound Healing: Enhanced tissue repair
- Reduced Inflammation: M2 polarization
- Neuroprotection: In some disease models
- Altered Metabolism: Changed polyamine levels
| Brain Region |
Expression Level |
Cell Type |
| Cortex |
Moderate |
Astrocytes, microglia |
| Hippocampus |
High |
Astrocytes, neurons |
| Substantia Nigra |
Moderate |
Microglia, astrocytes |
| Spinal Cord |
High |
Microglia (especially in disease) |
| Cerebellum |
Low |
Purkinje cells |
- Astrocytes: High ARG1 expression, particularly in gray matter
- Microglia: Inducible expression, marks M2 polarization
- Neurons: Lower basal expression, activity-dependent
- Oligodendrocytes: Minimal expression
- Mice: Higher basal arginase expression
- Rats: Similar to human expression patterns
- Humans: More restricted expression, highly inducible
ARG1 expression is controlled by:
- IL-4/IL-13: STAT6-dependent activation
- Glucocorticoids: Dexamethasone induces expression
- cAMP: PKA-dependent signaling
- Hypoxia: HIF-1α involvement
- TGF-β: SMAD-dependent pathway
Key signaling pathways regulating ARG1:
- JAK/STAT: IL-4/IL-13 signaling
- PI3K/Akt: Growth factor signaling
- MAPK: Stress-activated pathways
- NF-κB: Can be both positive and negative
- mRNA Stability: AU-rich elements in 3' UTR
- MicroRNAs: miR-155 targets ARG1, miR-182
- Alternative Splicing: Minor isoforms
- RNA-Binding Proteins: HuR, TTP involvement
- Phosphorylation: Serine/threonine residues
- Acetylation: Lysine acetylation affects activity
- Ubiquitination: Targets for degradation
- Sumoylation: Affects protein localization
ARG1 polymorphisms have been studied in:
- Cardiovascular Disease: Association with hypertension
- Asthma: Reduced arginase activity
- Neurological Disorders: Conflicting results in AD/PD
- Smoking: Affects arginase expression
- Diet: Arginine availability influences metabolism
- Exercise: Upregulates arginase in muscle
- NOS isoforms: eNOS, iNOS, nNOS compete for substrate
- ODC: Polyamine synthesis pathway
- GATA factors: Transcriptional regulation
- 14-3-3 proteins: Phosphorylation-dependent binding
- Arginine: Direct substrate
- Ornithine: Direct product
- Urea: Direct product
- Polyamines: Downstream metabolites
- Biomarker: M2 microglial marker
- Disease Progression: Levels correlate with progression
- Therapeutic Monitoring: Response to therapy
Targeting ARG1 in neurodegeneration involves:
- Inhibition: Reduce arginase activity
- Modulation: Fine-tune activity
- Delivery: Brain-penetrant compounds
- Combination: With anti-inflammatory drugs
- Blood-Brain Barrier: Drug delivery
- Selectivity: Isoform specificity
- Timing: Intervention window
- Side Effects: Systemic arginase inhibition
ARG1 is evolutionarily conserved:
- Vertebrates: Highly conserved sequence
- Invertebrates: Functional orthologs
- Bacteria: Different enzyme families
- Plants: Different enzyme families
- ARG1: Cytosolic, liver-type
- ARG2: Mitochondrial, kidney-type
- ARG3: Tissue-specific variants
- Mice: Two arginase genes (Arg1, Arg2)
- Zebrafish: Conserved function
- Humans: ARG1, ARG2, ARG3
- Precise role in specific neurodegenerative diseases
- Cell-type specific functions
- Long-term effects of modulation
- Interaction with other metabolic pathways
- Biomarker validation in clinical settings
Active areas of investigation include:
- How does ARG1 contribute to specific disease phenotypes?
- Can arginase modulation improve outcomes?
- What are the long-term effects of arginase targeting?
- What is the cell-type specific role in neurodegeneration?
- Single-cell studies: Cell-type specific roles
- Temporal dynamics: Time course of changes
- Mechanistic studies: Causal relationships
- Therapeutic development: Drug discovery
- CRISPR: Gene editing approaches for precise modulation
- Single-cell RNA-seq: Cellular resolution of expression patterns
- Proteomics: Protein interaction network mapping
- Metabolomics: Comprehensive metabolic pathway analysis
- Organoid models: Human-derived brain models for study
- CRISPR screening: Genome-wide functional studies
- Spatial transcriptomics: Tissue-level gene expression mapping
Key considerations for bringing arginase-based therapies to clinic:
- Pharmacokinetics: Ensuring adequate brain penetration
- Target engagement: Measuring target inhibition in vivo
- Biomarker development: Patient selection and response monitoring
- Safety profiling: Long-term effects of modulation
- Combination strategies: Synergy with existing therapies